Arana Therapeutics
Arana Therapeutics
The New Company
2007 Highlights
Chairman's Address
CEO's Address
Product Pipeline
Inflammation Franchise
Cancer Franchise
Bone Cancer and
Associated Bone Loss
Arana Therapeutics
Technology Platform
Intellectual Property
Management Team
The Board of Directors
Scientific Advisory Board
Financials
 

Intellectual property

Arana’s patent position reflects the new company’s focus on ensuring market exclusivity for lead therapeutic products in development. The company continues to pursue an aggressive policy of patenting discoveries and maximising patent coverage, with continual assessment of our own inventions and those of others in related areas that may impact on commercialisation of Arana’s products.

Arana’s current portfolio consists of 42 patent families with protection for its inventions being sought in major competitive markets including the US, Europe, Japan, Canada, Australia, China and India.

Arana scientists are aware of the importance of patents to the company and pay careful attention to the possibility of filing further applications as projects progress.		  

Patent families – income generation
Several of Arana’s patent families form the basis of the company’s income. Some of the patents listed below relate to anti-TNF (tumour necrosis factor), antibody humanisation by Superhumanisation™ and affinity maturation by Evogene™ technologies.

PCT Number PCT Title Filing Date
PCT/AU90/00337 Tumour necrosis factor binding ligands 7 September 1990
PCT/AU99/00341 Continuous in-vitro evolution 7 May 1999
PCT/AU03/01455
 Mutagenesis methods using ribavirin and/or
RNA replicases		 3 November 2003
PCT/US02/022011 Super humanized antibodies 12 July 2002

Patent families – product development
In the course of developing therapeutic products, Arana aims to prosecute existing patents and file new applications. Some key patents relating to our lead projects including ART621, ART010, ART150, ART104 and PMX53 are listed below.

PCT Number PCT Title Filing Date
PCT/AU2006/001940 Anti-inflammatory dAb 20 December 2006
PCT/AU2007/000085 Domain antibody construct 1 February 2007
PCT/GB2005/001805


 Monoclonal antibody SC104 and derivative
thereof specifically binding to a sialyltetraosyl
carbohydrate as a potential anti-tumour
therapeutic agent		 11 May 2005
PCT/AU05/001877 Osteoprotegerin variant proteins 13 December 2005
PCT/US00/19589 Anti-tumour antibodies, proteins and uses thereof 18 July 2000
PCT/AU98/00490

Cyclic agonists and antagonists of C5a receptors
and G-protein-coupled receptors

 25 June 1998